 |
|
|
| |
High SVR Rates With ABT-493 + ABT-530 in Non-Cirrhotic Patients With HCV Genotypes 1, 2, 3 Infection
|
| |
| |
Reported by Jules Levin
25th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 20-24 February 2016, Tokyo, Japan
[97-100% SVR]
Fred Poordad1, Paul Y Kwo2, Tarek Hassanein3, Armen Asatryan4, Stanley Wang4, David Wyles5, Mark S Sulkowski6 Hugo E Vargas7, Peter Ruane8, Franco Felizarta9, Humberto Aguilar10, Jacob Lalezari11, J Scott Overcash12 Michael Bennett 13, Benedict Maliakkal14, Asma Siddique15, Bal Raj Bhandari16, Teresa I Ng4, Ran Liu4, Chih-Wei Lin4, Sandra Lovell4, Federico J Mensa4, Jens Kort4
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States; 2Indiana University School of Medicine, Indianapolis, Indiana, United States; 3Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5University of California San Diego, La Jolla, California, United States; 6Johns Hopkins University School of Medicine, Balti more, Maryland, United States; 7Mayo Clinic, Phoenix, Arizona, United States; 8Ruane Medical & Liver Health Institute, Los Angeles, California, United States; 9Private practi ce, Bakersfield, California, United States; 10Louisiana Research Center, Shreveport, Louisiana, United States; 11Quest Clinical Research, San Francisco, California, United States; 12eStudySite, San Diego, California, United States; 13San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, California, United States; 14University of Rochester Medical Center, Rochester, New York, United States; 15Virginia Mason Hospital and Medical Center, Seattle, Washington, United States; 16Gastroenterology & Nutritional Medical Services, Bastrop, Louisiana, United States
|
| |
|
|
|
|
|
